189 related articles for article (PubMed ID: 24787737)
1. Efficacy and safety of levofloxacin in patients with bacterial pneumonia evaluated according to the new "Clinical Evaluation Methods for New Antimicrobial Agents to Treat Respiratory Infections (Second Version)".
Mukae H; Kawanami T; Yatera K; Yanagihara K; Yamamoto Y; Kakeya H; Tokimatsu I; Kadota J; Kohno S
J Infect Chemother; 2014 Jul; 20(7):417-22. PubMed ID: 24787737
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
3. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of levofloxacin in patients with nursing and healthcare-associated pneumonia].
Yamasaki K; Yatera K; Kawanami T; Sasahara Y; Hata R; Uchimura K; Tachiwada T; Naito K; Kato K; Takaki T; Shimabukuro I; Shiraishi T; Oda K; Hara K; Chojin Y; Suzuki Y; Akata K; Ogoshi T; Tokuyama S; Inoue N; Noguchi S; Nishida C; Orihashi T; Yoshida Y; Kawanami Y; Taura Y; Ishimoto H; Obata H; Awaya Y; Tsuda T; Yoshii C; Mukae H
Jpn J Antibiot; 2014 Feb; 67(1):23-32. PubMed ID: 24809206
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia.
Liu Y; Zhang Y; Wu J; Zhu D; Sun S; Zhao L; Wang X; Liu H; Ren Z; Wang C; Xiu Q; Xiao Z; Cao Z; Cui S; Yang H; Liang Y; Chen P; Lv Y; Hu C; Lv X; Liu S; Kuang J; Li J; Wang D; Chang L
J Microbiol Immunol Infect; 2017 Dec; 50(6):811-820. PubMed ID: 26748734
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of intravenous sulbactam/ampicillin 3 g 4 times daily in Japanese adults with moderate to severe community-acquired pneumonia: a multicenter, open-label, uncontrolled study.
Kohno S; Tateda K; Mikamo H; Kadota J; Niki Y; Itamura R
J Infect Chemother; 2015 Mar; 21(3):182-8. PubMed ID: 25533886
[TBL] [Abstract][Full Text] [Related]
7. Oral levofloxacin in the treatment of community-acquired pneumonia.
Nicodemo AC; Lima Nicodemo E; Idrahim KY
Braz J Infect Dis; 2000 Apr; 4(2):61-6. PubMed ID: 10795070
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of health care-associated pneumonia empirically treated with guideline-concordant regimens versus community-acquired pneumonia guideline-concordant regimens for patients admitted to acute care wards from home.
Chen JI; Slater LN; Kurdgelashvili G; Husain KO; Gentry CA
Ann Pharmacother; 2013 Jan; 47(1):9-19. PubMed ID: 23324506
[TBL] [Abstract][Full Text] [Related]
10. Clinical features of healthcare-associated pneumonia (HCAP) in a Japanese community hospital: comparisons among nursing home-acquired pneumonia (NHAP), HCAP other than NHAP, and community-acquired pneumonia.
Umeki K; Tokimatsu I; Yasuda C; Iwata A; Yoshioka D; Ishii H; Shirai R; Kishi K; Hiramatsu K; Matsumoto B; Kadota J
Respirology; 2011 Jul; 16(5):856-61. PubMed ID: 21545370
[TBL] [Abstract][Full Text] [Related]
11. Analysis of clinical efficacy of different initial antimicrobial treatment in healthcare associated pneumonia patients in emergency department.
Cao G; Chen X; Wu S
Chin Med J (Engl); 2014; 127(10):1814-9. PubMed ID: 24824237
[TBL] [Abstract][Full Text] [Related]
12. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
[TBL] [Abstract][Full Text] [Related]
13. Contradiction between in vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia.
Kohno S; Tateda K; Kadota J; Fujita J; Niki Y; Watanabe A; Nagashima M
J Infect Chemother; 2014 Mar; 20(3):199-207. PubMed ID: 24477328
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China.
Zhang YY; Huang HH; Ren ZY; Zheng HG; Yu YS; Lü XJ; Xiao ZK; Yang HF; Xiu QY; Chen BY; Yue HM; Hao QL; Huang JA; Ma H; Xiao W; Guo DY; Si B; Sun SH; Zhang W; Li QH; Shen HH; Duan J; Li HY; Yao WZ; Gu JM; Xia QM; Ying KJ; Liu A; Yang HP; Shi MH; Sun TY; Ding GH; Wu GM
J Infect Chemother; 2009 Oct; 15(5):301-11. PubMed ID: 19856068
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled clinical trial of levofloxacin 750 mg versus 500 mg intravenous infusion in the treatment of community-acquired pneumonia.
Zhao X; Wu JF; Xiu QY; Wang C; Zhang DP; Huang JA; Xie CM; Sun SH; Lv XJ; Si B; Xiao ZK; Zhang YY
Diagn Microbiol Infect Dis; 2014 Oct; 80(2):141-7. PubMed ID: 25130297
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the in Vivo Activities of Garenoxacin and Levofloxacin in a Murine Model of Pneumonia by Mixed-Infection with Streptococcus pneumoniae and Parvimonas micra.
Kato H; Hagihara M; Yokoyama Y; Suematsu H; Asai N; Koizumi Y; Yamagishi Y; Mikamo H
Jpn J Infect Dis; 2019 Nov; 72(6):407-412. PubMed ID: 31366860
[TBL] [Abstract][Full Text] [Related]
17. [Factors effecting the duration of hospitalization and mortality in patients with community-acquired pneumonia].
Pişkin N; Aydemir H; Oztoprak N; Akduman D; Celebi G; Seremet Keskin A
Mikrobiyol Bul; 2009 Oct; 43(4):597-606. PubMed ID: 20084912
[TBL] [Abstract][Full Text] [Related]
18. Prospective clinical evaluation of 1.5% levofloxacin ophthalmic solution in ophthalmic perioperative disinfection.
Suzuki T; Tanaka H; Toriyama K; Okamoto S; Urabe K; Hashida M; Shinkai Y; Ohashi Y
J Ocul Pharmacol Ther; 2013 Dec; 29(10):887-92. PubMed ID: 24180629
[TBL] [Abstract][Full Text] [Related]
19. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Tanaseanu C; Bergallo C; Teglia O; Jasovich A; Oliva ME; Dukart G; Dartois N; Cooper CA; Gandjini H; Mallick R; ;
Diagn Microbiol Infect Dis; 2008 Jul; 61(3):329-38. PubMed ID: 18508226
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.
Yuan J; Mo B; Ma Z; Lv Y; Cheng SL; Yang Y; Tong Z; Wu R; Sun S; Cao Z; Wu J; Zhu D; Chang L; Zhang Y;
J Microbiol Immunol Infect; 2019 Feb; 52(1):35-44. PubMed ID: 30181096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
